Bellecapital’s Elevance Health ELV Stock Holding History

Bellecapital’s Portfolio ELV Stock Details ELV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-928	Closed	-$244K	–	166
2020 Q2	$244K	Hold	928	–	–	0.11%	133
2020 Q1	$211K	Buy	+928	New	+$253K	0.14%	131

Other funds holding ELV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Bellecapital's ELV Position: Q3 2020 in Review

Bellecapital sold out of Elevance Health (ELV) in Q3 2020, closing a stake of 928 shares — an estimated $244K sold.

Bellecapital first reported a position in ELV in Q1 2020 and held it in 2 quarters. The position peaked at $244K in Q2 2020. 1,094 funds tracked by Wall St. Rank hold ELV as of Q3 2020.

Bellecapital reported no remaining Elevance Health position as of Q3 2020 after selling out during the quarter.
Bellecapital sold 928 Elevance Health shares in Q3 2020, an estimated $244K.
Bellecapital first reported a position in Elevance Health in Q1 2020 and held it in 2 quarters.
Bellecapital's Elevance Health position peaked at $244K in Q2 2020.
1,094 funds tracked by Wall St. Rank held Elevance Health as of Q3 2020.

Based on Bellecapital's 13F filing for Q3 2020, filed 16 Oct 2020.